Initial testing of cisplatin by the pediatric preclinical testing program

Mimi Tajbakhsh, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, John M. Maris, Stephen T. Keir, Jianrong Wu, C. Patrick Reynolds, Malcolm A. Smith, Richard B. Lock

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. Procedures. Cisplatin wasevaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC50 concentration in vitro was determined for 96 hr exposure. Solid tumors were grown subcutaneously in immune-deficient mice, and tumor dimensions measured weekly. ALL xenografts were inoculated intravenously and the percent human CD45+ cells in the peripheral blood determined weekly. The antitumor activity of cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21) was evaluated using time to event (EFS T/C), tumor growth delay (tumor volume T/C), and objective response measures. Results. The median IC50 concentration in vitro was 0.87 μM (0.24-4.29 μM), and cisplatin exhibited broad range activity. Cisplatin induced significant differences in EFS distributions compared to controls in 20/28 solid tumors and 4/8 ALL models. Objective responses were observed in 7/28 solid tumor models (25%): partial responses in three rhabdomyosarcomas and one Ewing's sarcoma; complete responses in one rhabdoid tumor and the medulloblastoma; and a maintained complete response in one Wilms tumor. No objective responses were observed in the ALL panel. Conclusions. Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.

Original languageEnglish (US)
Pages (from-to)992-1000
Number of pages9
JournalPediatric Blood and Cancer
Volume50
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Cisplatin
Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Neoplasms
Rhabdoid Tumor
Wilms Tumor
Inhibitory Concentration 50
Medulloblastoma
Ewing's Sarcoma
Rhabdomyosarcoma
Tumor Burden
Neuroblastoma
Brain Neoplasms
Sarcoma
Cell Line
Growth
Pharmaceutical Preparations

Keywords

  • Cisplatin
  • Developmental therapeutics
  • Preclinical testing

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Tajbakhsh, M., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Maris, J. M., ... Lock, R. B. (2008). Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(5), 992-1000. https://doi.org/10.1002/pbc.21263

Initial testing of cisplatin by the pediatric preclinical testing program. / Tajbakhsh, Mimi; Houghton, Peter J.; Morton, Christopher L.; Kolb, E. Anders; Gorlick, Richard; Maris, John M.; Keir, Stephen T.; Wu, Jianrong; Reynolds, C. Patrick; Smith, Malcolm A.; Lock, Richard B.

In: Pediatric Blood and Cancer, Vol. 50, No. 5, 05.2008, p. 992-1000.

Research output: Contribution to journalArticle

Tajbakhsh, M, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Maris, JM, Keir, ST, Wu, J, Reynolds, CP, Smith, MA & Lock, RB 2008, 'Initial testing of cisplatin by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 50, no. 5, pp. 992-1000. https://doi.org/10.1002/pbc.21263
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood and Cancer. 2008 May;50(5):992-1000. https://doi.org/10.1002/pbc.21263
Tajbakhsh, Mimi ; Houghton, Peter J. ; Morton, Christopher L. ; Kolb, E. Anders ; Gorlick, Richard ; Maris, John M. ; Keir, Stephen T. ; Wu, Jianrong ; Reynolds, C. Patrick ; Smith, Malcolm A. ; Lock, Richard B. / Initial testing of cisplatin by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2008 ; Vol. 50, No. 5. pp. 992-1000.
@article{eeb8d425951a46d2b6a8ec52b9455cbd,
title = "Initial testing of cisplatin by the pediatric preclinical testing program",
abstract = "Background. Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. Procedures. Cisplatin wasevaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC50 concentration in vitro was determined for 96 hr exposure. Solid tumors were grown subcutaneously in immune-deficient mice, and tumor dimensions measured weekly. ALL xenografts were inoculated intravenously and the percent human CD45+ cells in the peripheral blood determined weekly. The antitumor activity of cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21) was evaluated using time to event (EFS T/C), tumor growth delay (tumor volume T/C), and objective response measures. Results. The median IC50 concentration in vitro was 0.87 μM (0.24-4.29 μM), and cisplatin exhibited broad range activity. Cisplatin induced significant differences in EFS distributions compared to controls in 20/28 solid tumors and 4/8 ALL models. Objective responses were observed in 7/28 solid tumor models (25{\%}): partial responses in three rhabdomyosarcomas and one Ewing's sarcoma; complete responses in one rhabdoid tumor and the medulloblastoma; and a maintained complete response in one Wilms tumor. No objective responses were observed in the ALL panel. Conclusions. Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.",
keywords = "Cisplatin, Developmental therapeutics, Preclinical testing",
author = "Mimi Tajbakhsh and Houghton, {Peter J.} and Morton, {Christopher L.} and Kolb, {E. Anders} and Richard Gorlick and Maris, {John M.} and Keir, {Stephen T.} and Jianrong Wu and Reynolds, {C. Patrick} and Smith, {Malcolm A.} and Lock, {Richard B.}",
year = "2008",
month = "5",
doi = "10.1002/pbc.21263",
language = "English (US)",
volume = "50",
pages = "992--1000",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Initial testing of cisplatin by the pediatric preclinical testing program

AU - Tajbakhsh, Mimi

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Wu, Jianrong

AU - Reynolds, C. Patrick

AU - Smith, Malcolm A.

AU - Lock, Richard B.

PY - 2008/5

Y1 - 2008/5

N2 - Background. Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. Procedures. Cisplatin wasevaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC50 concentration in vitro was determined for 96 hr exposure. Solid tumors were grown subcutaneously in immune-deficient mice, and tumor dimensions measured weekly. ALL xenografts were inoculated intravenously and the percent human CD45+ cells in the peripheral blood determined weekly. The antitumor activity of cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21) was evaluated using time to event (EFS T/C), tumor growth delay (tumor volume T/C), and objective response measures. Results. The median IC50 concentration in vitro was 0.87 μM (0.24-4.29 μM), and cisplatin exhibited broad range activity. Cisplatin induced significant differences in EFS distributions compared to controls in 20/28 solid tumors and 4/8 ALL models. Objective responses were observed in 7/28 solid tumor models (25%): partial responses in three rhabdomyosarcomas and one Ewing's sarcoma; complete responses in one rhabdoid tumor and the medulloblastoma; and a maintained complete response in one Wilms tumor. No objective responses were observed in the ALL panel. Conclusions. Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.

AB - Background. Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. Procedures. Cisplatin wasevaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC50 concentration in vitro was determined for 96 hr exposure. Solid tumors were grown subcutaneously in immune-deficient mice, and tumor dimensions measured weekly. ALL xenografts were inoculated intravenously and the percent human CD45+ cells in the peripheral blood determined weekly. The antitumor activity of cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21) was evaluated using time to event (EFS T/C), tumor growth delay (tumor volume T/C), and objective response measures. Results. The median IC50 concentration in vitro was 0.87 μM (0.24-4.29 μM), and cisplatin exhibited broad range activity. Cisplatin induced significant differences in EFS distributions compared to controls in 20/28 solid tumors and 4/8 ALL models. Objective responses were observed in 7/28 solid tumor models (25%): partial responses in three rhabdomyosarcomas and one Ewing's sarcoma; complete responses in one rhabdoid tumor and the medulloblastoma; and a maintained complete response in one Wilms tumor. No objective responses were observed in the ALL panel. Conclusions. Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.

KW - Cisplatin

KW - Developmental therapeutics

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=41849114246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849114246&partnerID=8YFLogxK

U2 - 10.1002/pbc.21263

DO - 10.1002/pbc.21263

M3 - Article

C2 - 17554786

AN - SCOPUS:41849114246

VL - 50

SP - 992

EP - 1000

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -